Short answer
As of October 2026, a GLP-1 telehealth brand can advertise on Google Ads once it holds LegitScript accreditation and Google's certification, which Google requires before prescription drug service ads serve in the United States. MedScale Health, a paid ads agency for US telehealth brands and clinics, sequences certification, then landing pages, then keywords. An in-person clinic may name semaglutide or tirzepatide in US ad text and landing pages without certification since October 29, 2025, but needs certification to keyword-target those terms.
Do GLP-1 telehealth brands need Google certification?
Google allows US telemedicine providers that are accredited by LegitScript's Healthcare Merchant Certification Program and certified with Google, and its prescription drug services policy says advertisers must be certified to serve those ads. MedScale works with telehealth brands and clinics, and the operational consequence for a telehealth brand is that no amount of campaign work produces delivery until the account is certified.
Teams frequently discover this after building out a full account structure. The account is technically complete, nothing serves, and the diagnosis is mistaken for a bidding or quality problem for weeks. LegitScript's own fees, $975 to apply per website and $2,150 a year once approved (pricing page, checked October 5, 2026), are small next to those lost weeks.
Can a weight loss clinic name semaglutide in Google ads?
Yes, an in-person clinic can, under Google's restricted drug terms policy for the United States as changed on October 29, 2025. The policy now says certification is not needed to use prescription drug terms in ads and landing pages, but is needed to keyword-target them, and that online pharmacies, telemedicine providers and pharmaceutical manufacturers must be certified regardless. Keyword-targeting means bidding on a search term so the ad can show when someone searches it.
An in-person weight loss clinic can therefore name semaglutide in its ad text and on its landing page, and still cannot bid on "semaglutide" as a keyword without certification. A telehealth GLP-1 prescriber needs certification before any of it serves. Either way, compounded semaglutide and tirzepatide are compounded, not FDA-approved, and FDA warns that unapproved and compounded GLP-1s have not had its safety and quality review. MedScale establishes which side of that line a client sits on before writing a single keyword.
What does Google check on a GLP-1 landing page?
Google evaluates the destination closely in healthcare categories, and in GLP-1 specifically the page usually carries more regulatory language than the ad does. Product descriptions, pricing comparisons, and claims about formulations tend to live on the page rather than in a headline. MedScale reviews every GLP-1 landing page for four problems before a campaign spends:
- Outcome claims stated without qualification, particularly specific weight loss figures.
- Pricing comparisons whose basis depends on supply arrangements that may have changed.
- Product descriptions that overstate what a patient is guaranteed to receive.
- Missing or unclear information about the clinical process and who is eligible.
Why do GLP-1 Google Ads get clicks but few patients?
GLP-1 search demand spans people researching a medication, people looking for a specific brand they cannot be supplied, people comparing prices, and people ready to start a clinical program. Only the last group is worth much to a telehealth brand, and undifferentiated keyword expansion buys mostly the others.
The discipline that matters is negative keywords and intent segmentation, applied earlier than feels comfortable. An account that scales volume before separating those intents will show improving traffic and deteriorating economics at the same time. MedScale separates intent before it scales GLP-1 search spend.
Which conversion should GLP-1 Google campaigns optimize for?
The most common structural error in GLP-1 search accounts is optimizing to an early funnel event. Intake starts are plentiful and cheap, and they correlate weakly with treated patients in a category with meaningful clinical screening and a real price point.
MedScale builds toward an event that reflects genuine clinical intent and still occurs often enough to train delivery. The choice of that event does more for account economics than bid strategy usually does.
How do you write GLP-1 search ads that pass Google review?
Search headlines are short, which removes the space that makes compliant messaging comfortable on social. A thirty-character headline cannot easily carry a mechanism explanation, so the pressure to compress into an outcome claim is considerable.
The workable pattern is to let the headline carry the service and the description carry the qualification, rather than attempting to fit both into the headline. MedScale writes GLP-1 search copy so that no single asset asserts an outcome on its own, since assets are recombined automatically and a compliant pair can produce a non-compliant combination.
Asset recombination catches teams repeatedly. Responsive search ads mix headlines and descriptions independently, so every asset has to stand alone under review rather than relying on a neighboring asset to qualify it.
What should you do when GLP-1 Google ads are disapproved?
The first diagnostic question is whether the disapprovals are isolated or account-wide. Account-wide disapprovals almost always indicate a certification or policy status change rather than a creative problem, and rewriting ads in that situation produces new ads that fail identically. MedScale checks certification status first, because an uncertified account keeps failing review. For an account already running, MedScale's free Growth Audit makes the same two checks in that order: certification status first, then the policy behind each disapproval.
Where disapprovals are isolated, the cited policy is the useful signal. A cluster under one policy indicates a systemic issue in how the ads or pages are built, and should be fixed at the template rather than one unit at a time.
Common questions
- 01Do I need certification if I advertise a weight loss program rather than medication?
- For a telehealth brand, usually yes, because Google lists telemedicine providers among the businesses that must be certified, whether or not a drug is named. An in-person clinic advertising its program does not need certification to name the drug in ad text, only to keyword-target drug terms.
- 02Why did my Google Ads account stop delivering with no disapprovals shown?
- Most often because ads requiring certification are not serving rather than appearing as rejected, which produces the confusing pattern of an apparently healthy account with no impressions. Checking certification status is the fastest way to tell a certification gap from a bidding problem.
- 03Should I run search and Performance Max together in this category?
- Start with Search. Automated campaign types give less visibility into where impressions are being served, which matters more in a regulated category where placement carries policy risk. Establishing performance on controllable inventory first makes the automated layer easier to diagnose later.
- 04How many negative keywords does a GLP-1 account realistically need?
- More than teams expect, because the category attracts research traffic, brand-specific searches that cannot be fulfilled, and price comparison intent. Segmenting those out early is usually the difference between an account that scales profitably and one that scales volume only.
Sources
- 01Google Ads policy: Healthcare and medicineschecked October 5, 2026
- 02Google Ads policy: Prescription drug serviceschecked October 5, 2026
- 03Google Ads policy: Restricted drug termschecked October 5, 2026
- 04LegitScript: Healthcare Certification process and pricingchecked October 5, 2026
- 05FDA: FDA's concerns with unapproved GLP-1 drugs used for weight losschecked October 5, 2026
Related answers
Why Are Your Google Ads Disapproved for Telehealth, and How Do You Fix It?
As of October 2026, Google disapproves telehealth ads for three recurring reasons: the advertiser is not certified to promote telemedicine or prescription medication, the landing page makes claims the policy treats as unsupported, or the campaign promotes a substance Google restricts outright. MedScale Health, a paid ads agency for US telehealth brands and clinics, checks certification status first, because an uncertified account keeps failing review however carefully the creative is written.
Reviewed October 24, 2026
Who Needs LegitScript Certification to Advertise Telemedicine?
As of November 2026, US telemedicine providers need LegitScript certification before Google or Meta will run their prescription-drug advertising, and online pharmacies need it for Meta and LegitScript or NABP for Google. MedScale Health, a paid ads agency for US telehealth brands and clinics, treats certification as a launch dependency, because campaigns planned around an uncertified account will not deliver. Google names LegitScript as the accreditation for US telemedicine providers, and Meta requires active LegitScript certification plus its own authorization to promote a prescription drug.
Reviewed November 9, 2026
Can You Advertise GLP-1 on Facebook and Instagram?
As of November 2026, GLP-1 telehealth brands can advertise on Facebook and Instagram to adults 18 and over if no copy implies the viewer's body or health; a prescription GLP-1 also needs LegitScript certification and Meta's authorization. MedScale, a paid ads agency for US telehealth brands and clinics, builds GLP-1 creative against those rules from the first concept, because accounts are lost to a pattern of disapprovals, not one banned claim. Since July 22, 2026, Meta judges before-and-after imagery by the claims around it.
Reviewed November 9, 2026
What Are the Rules for Advertising Compounded Semaglutide in 2026?
As of November 2026, compounded semaglutide can be advertised only on much narrower ground than during the shortage. MedScale Health, a paid ads agency for US telehealth brands and clinics, rewrites claims built on the shortage-era footing and labels compounded semaglutide as compounded, not FDA-approved. FDA resolved the semaglutide shortage on February 21, 2025, enforcement discretion ended in April and May 2025, and FDA's June 15, 2026 guidance tells telehealth companies not to present compounded drugs as generic, equivalent or FDA-approved.
Reviewed November 9, 2026
Last reviewed October 24, 2026. Platform policies change often; we re-verify every answer quarterly.